PTGS2 and non-small cell lung carcinoma: Considering that most patients were in stages II–IV, we also conducted the same analysis in two stages I–II NSCLC datasets and found that CXCL1 was significantly associated with prognosis in the GSE31210 dataset (HR = 1.42, 95% CI: 1.12–1.81, p < .01) and PTGS2 in the GSE50081 dataset (HR = 1.18, 95% CI: 1.05–1.32, p < .01; Figure 8G,H).